Heart failure with preserved ejection fraction based on aging and comorbidities

Heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause of hospitalizations and mortality when diagnosed at the age of ≥ 65 years. HFpEF represents multifactorial and multisystemic syndrome and has different pathophysiology and phenotypes. Its diagnosis is difficult to be esta...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 19; no. 1; pp. 1 - 13
Main Authors Lin, Ying, Fu, Shihui, Yao, Yao, Li, Yulong, Zhao, Yali, Luo, Leiming
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 06.07.2021
BioMed Central
BMC
Subjects
Age factors in disease
Aging
Analysis
Cardiac catheterization
Cardiac function
Cardiovascular disease
Care and treatment
Clinical medicine
Comorbidities
Comorbidity
Complications and side effects
Congestive heart failure
Development and progression
Diabetes
Diagnosis
Disease prevention
Dyspnea
Ejection fraction
Exercise
Heart failure
Heart failure with preserved ejection fraction
Hypertension
Inflammation
Intubation
Metabolism
Mortality
Mutation
Obesity
Peptides
Phenotypes
Physical fitness
Pulmonary arteries
Review
Risk factors
Treatment
Ventricle
Weight control
China
Online AccessGet full text

Cover

More Information
Summary:Heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause of hospitalizations and mortality when diagnosed at the age of ≥ 65 years. HFpEF represents multifactorial and multisystemic syndrome and has different pathophysiology and phenotypes. Its diagnosis is difficult to be established based on left ventricular ejection fraction and may benefit from individually tailored approaches, underlying age-related changes and frequent comorbidities. Compared with the rapid development in the treatment of heart failure with reduced ejection fraction, HFpEF presents a great challenge and needs to be addressed considering the failure of HF drugs to improve its outcomes. Further extensive studies on the relationships between HFpEF, aging, and comorbidities in carefully phenotyped HFpEF subgroups may help understand the biology, diagnosis, and treatment of HFpEF. The current review summarized the diagnostic and therapeutic development of HFpEF based on the complex relationships between aging, comorbidities, and HFpEF.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-021-02935-x